2nd Quarter - Amendment

NATIONAL KIDNEY FOUNDATION for NATIONAL KIDNEY FOUNDATION

Firm
Client
Income
—
Expenses
$90,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 20, 2025 $90,000 Replaced
2nd Quarter - Amendment (this page) Aug 14, 2025 $90,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

FY 2026 Appropriations for organ donation and transplantation activities (HRSA). FY 2026 Appropriations for CDC, including the Chronic Kidney Disease Initiative. FY 2026 Appropriations for kidney research at the National Institute of Diabetes and Digestive and Kidney Diseases. FY 2026 Appropriations for Indian Health Service.

LobbyistCovered position, as disclosed
LAUREN DREW —
TROY ZIMMERMAN —

Contacted: Indian Health Service; Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); SENATE

Health Issues HCR

Activities to facilitate organ donation and transplantation, including the Honor our Living Donors Act (H.R. 628, S. 957) to modify criteria to determine eligibility to reimburse individuals under the Living Organ Donation Reimbursement Program, and the Living Donor Protection Act (S.1552) to prohibit discrimination in life, disability and long-term health coverage policies. Comments on proposed "Revisions to Human Immunodeficiency Virus (HIV) Policies to Align with Federal Regulatory Updates," from the Organ Procurement and Transplantation Networks (OPTN) Disease Transmission Advisory Committee. Implementation of P.L. 118-14, "Securing the U.S. Organ Procurement and Transplantation Network Act." Implementation of the Advancing American Kidney Health Initiative. Support for telemedicine and telehealth access. General activities in support of access to affordable, accessible health care. Opposed changes to Affordable Care Act eligibility, access and affordability under the One Big Beautiful Bill (H.R. 1).

LobbyistCovered position, as disclosed
LAUREN DREW —
MIRIAM ELIZABETH GODWIN —
MORGAN REID —
JESSE ROACH —
TROY ZIMMERMAN —

Contacted: Health Resources & Services Administration (HRSA); Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: S. 957 (119th), H.R. 628 (119th), S. 1552 (119th), H.R. 1 (119th)

Medicare/Medicaid MMM

Initiatives to expand access to home dialysis (bill introduction pending). S.1973 and H.R. 4231, "Treat and Reduce Obesity Act," to provide Medicare coverage of anti-obesity medications and obesity treatment. Opposed changes to Medicaid eligibility, access and affordability of coverage under the One Big Beautiful Bill (H.R. 1). Activities to address detection and management of chronic kidney disease. Support for Medicare Part D Protected Classes. Implementation of the Advancing American Kidney Health Initiative.

LobbyistCovered position, as disclosed
LAUREN DREW —
MIRIAM ELIZABETH GODWIN —
MORGAN REID —
JESSE ROACH —
TROY ZIMMERMAN —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 1973 (119th), H.R. 1 (119th), H.R. 4231 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.